Free Trial
→ Many investors are about to lose everything (From Porter & Company) (Ad)tc pixel
NASDAQ:QNTM

Quantum Biopharma Earnings Date & Estimates

Quantum Biopharma logo
$2.06 -0.17 (-7.67%)
As of 02:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Quantum Biopharma is estimated to report earnings on Tuesday, November 10, 2026, after market closes.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Time
After Market Closes
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Quantum Biopharma

Quantum Biopharma is expected to post earnings of -$0.50 per share. In the same quarter a year earlier Quantum Biopharma reported -$1.25 per share. Quantum Biopharma last reported on August 13, 2026, posting -$0.47 per share and missing the -$0.4116 consensus estimate. Quantum Biopharma has beaten the consensus EPS estimate in 0 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.50
Prior-Year EPS
-$1.25

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.47 (Missed by -$0.0584)
EPS Beat Rate
0 of last 8 quarters

Prepare for the Earnings Call

Quantum Biopharma Earnings FAQ

Quantum Biopharma (NASDAQ:QNTM) is estimated to report earnings on Tuesday, November 10, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Quantum Biopharma to post earnings of -$0.50 per share for the quarter.

Quantum Biopharma Earnings Headlines

Quantum BioPharma (NASDAQ: QNTM) Advances Broad Strategy Anchored by Science, Disciplined Growth
November 5, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/currencies/quantum-biopharma-nasdaq-qntm-advances-broad-strategy-anchored-by-science-disciplined-growth-1036723904
Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies ...
November 5, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/quantum-biopharma-ltd-announces-filing-of-supplement-to-management-information-circular-correcting-fractional-share-treatment-under-proposed-share-consolidation-and-clarifies-mvs-voting-power-1036725714
Many investors are about to lose everything
Twenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.tc pixel
November 10 at 1:00 AM  |  Porter & Company (Ad)
Quantum BioPharma (QNTM) Advances Broad Strategy Anchored by Science, Disciplined Growth
November 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-advances-broad-200000032.html
Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Threshold
November 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/05/3397195/0/en/quantum-biopharma-ltd-announces-filing-of-supplement-to-management-information-circular-correcting-fractional-share-treatment-under-proposed-share-consolidation-and-clarifies-mvs-v.html
Quantum BioPharma (QNTM) Draws 'Men's Fitness' Spotlight as Unbuzzd Trial Shows Early Promise
November 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-draws-mens-203000469.html
See More Quantum Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email.

About Quantum Biopharma

Quantum Biopharma (NASDAQ:QNTM) is a biotechnology company focused on developing treatments for neurodegenerative and neurological disorders. Its lead drug candidate, Lucid-21-302, also known as Lucid-MS, is an orally administered small molecule being developed as a potential therapy for multiple sclerosis. The company is investigating the compound’s ability to protect nerve cells and promote remyelination, or the repair of damaged myelin.

Quantum BioPharma is also pursuing additional applications for its drug-development platform, including potential treatments for other neurodegenerative and mental health conditions. Through its subsidiaries and affiliated businesses, the company has also been involved in consumer health products, including unbuzzd, a beverage product marketed to help address the effects of alcohol consumption.

The company was formerly known as FSD Pharma Inc. and adopted the Quantum BioPharma name as it expanded its focus on pharmaceutical and biotechnology development. Quantum BioPharma is based in Toronto, Canada, and is led by Chairman and Chief Executive Officer Zeeshan Saeed. Its operations and development activities are primarily centered on advancing its pipeline of proprietary therapeutic candidates.

View Quantum Biopharma Profile
Earnings Tools